Search - tctmd.com

Displaying 361 - 380 of 499

Sort: Relevancy | Date

News Industry News

OrbusNeich Announces Initiation of HARMONEE Stent Study in US

May 18, 2015

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

News Daily News

Postdilation May Improve Outcomes After Self-Expanding Stent Is Used in Primary PCI

L.A. McKeown

March 18, 2015

News Daily News

DCB Matches DES in Treating ‘Real-World’ Patients With In-Stent Restenosis

March 04, 2015

News Daily News

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

L.A. McKeown

February 26, 2015

News Daily News

ZEUS Published: ZES With Personalized DAPT Bests Bare-Metal Stent in ‘Uncertain’ DES Candidates

L.A. McKeown

February 25, 2015

News Features

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

L.A. McKeown

January 28, 2015

News Daily News

DES With Biodegradable Polymer Safe, Durable Through 5 Years

L.A. McKeown

January 28, 2015

News Industry News

New Data From EVOLVE Clinical Program Demonstrate SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

November 18, 2014

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Conference News AHA 2014

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Yael L. Maxwell

November 16, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Conference News TCT 2014

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

September 19, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

September 13, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

News Daily News

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

L.A. McKeown

September 02, 2014

Advertisement

OrbusNeich Announces Initiation of HARMONEE Stent Study in US

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

Postdilation May Improve Outcomes After Self-Expanding Stent Is Used in Primary PCI

DCB Matches DES in Treating ‘Real-World’ Patients With In-Stent Restenosis

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

ZEUS Published: ZES With Personalized DAPT Bests Bare-Metal Stent in ‘Uncertain’ DES Candidates

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

DES With Biodegradable Polymer Safe, Durable Through 5 Years

New Data From EVOLVE Clinical Program Demonstrate SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

COMPARE II: BES, EES Show Similar Outcomes at Three Years

PROTECT: ZES Sustain Lead Over SES at 5 Years

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content